AlloVir Announces Proposed Public Offering of Common Stock
June 21 2023 - 4:18PM
Business Wire
AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy
company, today announced that it has commenced a proposed
underwritten public offering of $75.0 million of shares of its
common stock. AlloVir also intends to grant the underwriters a
30-day option to purchase up to an additional 15% of the total
number of shares of its common stock offered in the public
offering. All of the shares in the proposed offering are to be sold
by AlloVir. The proposed offering is subject to market and other
conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering.
J.P. Morgan, Morgan Stanley and BofA Securities are acting as
joint book-running managers for the proposed offering.
The shares are being offered by AlloVir pursuant to an effective
shelf registration statement that was previously filed with the
U.S. Securities and Exchange Commission (the “SEC”). The offering
is being made only by means of a written prospectus and prospectus
supplement that form a part of the registration statement. A
preliminary prospectus supplement relating to and describing the
terms of the offering will be filed with the SEC and will be
available on the SEC’s website at www.sec.gov.
When available, copies of the preliminary prospectus supplement
relating to the offering may be obtained from J.P. Morgan
Securities LLC, Attention: Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, New York 11717, telephone:
1-866-803-9204 or email at prospectus-eq_fi@jpmchase.com; from
Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180
Varick Street, 2nd Floor, New York, New York 10014, or by email at
prospectus@morganstanley.com; or from BofA Securities, Attention:
Prospectus Department, NC1-022-02-25, 201 North Tryon, Charlotte,
North Carolina 28255-0001, or by email at
dg.prospectus_requests@bofa.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such state or jurisdiction.
About AlloVir
AlloVir is a leading late clinical-stage cell therapy company
with a focus on restoring natural immunity against life-threatening
viral diseases in pediatric and adult patients with weakened immune
systems. The company’s innovative and proprietary technology
platforms leverage off-the-shelf, allogeneic, single- and
multi-virus-specific T cells for patients with T cell deficiencies
who are at risk from the life-threatening consequences of viral
diseases. AlloVir’s technology and manufacturing process enable the
potential for the treatment and prevention of a spectrum of
devastating viruses with each single allogeneic cell therapy. The
company is advancing multiple mid- and late-stage clinical trials
across its product portfolio.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230621939289/en/
Media and Investor: ir@allovir.com
AlloVir (NASDAQ:ALVR)
Historical Stock Chart
From Jun 2024 to Jul 2024
AlloVir (NASDAQ:ALVR)
Historical Stock Chart
From Jul 2023 to Jul 2024